Protocol for identifying properties of ERBB receptor antagonists using the barcoded ERBBprofiler assay.

Autor:	Popović L; Research Group Cell Signalling, Department of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, Nussbaumstr. 7, 80336 Munich, Germany; Systasy Bioscience GmbH, Balanstr. 6, 81669 Munich, Germany., Rossner MJ; Systasy Bioscience GmbH, Balanstr. 6, 81669 Munich, Germany; Section of Molecular Neurobiology, Department of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, Nussbaumstr. 7, 80336 Munich, Germany., Wehr MC; Research Group Cell Signalling, Department of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, Nussbaumstr. 7, 80336 Munich, Germany; Systasy Bioscience GmbH, Balanstr. 6, 81669 Munich, Germany. Electronic address: michael.wehr@med.uni-muenchen.de.
Jazyk:	angličtina
Zdroj:	STAR protocols [STAR Protoc] 2024 Jun 21; Vol. 5 (2), pp. 102987. Date of Electronic Publication: 2024 Apr 16.
DOI:	10.1016/j.xpro.2024.102987
Abstrakt:	The ERBBprofiler assay measures compound effects on ERBB family receptors and key downstream signaling pathways that are implicated in cancer or other complex diseases. Here, we present a protocol for identifying properties of ERBB receptor antagonists using the barcoded ERBBprofiler assay. We describe steps for in-solution transfection, cell treatment, combined processing of samples, amplification and indexing of PCRs, sequencing, and data analysis. This approach allows for the simultaneous assessment of drug effects and cell-type-dependent effects. For complete details on the use and execution of this protocol, please refer to Popović et al. 1 . Competing Interests: Declaration of interests M.J.R. and M.C.W. are employees and shareholders of Systasy Bioscience GmbH. (Copyright © 2024. Published by Elsevier Inc.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu